LONDON (Alliance News) - Oxford BioDynamics PLC on Monday said it has entered into a pilot development agreement with Singapore-based EpiFit PTE Ltd to analyse the effect of EpiFit's fitness regimes.
Under the agreement, Oxford BioDynamics will identify epigenetic biomarkers to help pick out and monitor volunteers and trainees who might benefit from EpiFit strength or endurance training programmes, using what it calls its 'EpiSwitch' platform.
After an initial project, Oxford BioDynamics has agreed to grant EpiFit the option of a multi-year global licence to use some EpiSwitch biomarker panels to provide screening services to third parties.
"It is well known that epigenetics profiles change in response to programmes of physical exercise and dietary regimes. Whether an individual is predisposed to and can benefit from a particular type of training would provide a highly valuable and practical guiding insight that will help across the full spectrum of fitness training, from the highly professional end and all the way to every health-conscious member of the population at large," said Chief Executive Officer Christian Hoyer Millar in a statement.
Shares in Oxford BioDynamics were up 1.5% at 149.25 pence Monday.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2017 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)